Pharma Sector

* Span of drugs under price control to be drastically reducded; Government holds the right to intervene in favour of the poor

* 150% weighted deduction on R&D expenses extended to biotech industry and for carrying out clinical trials, and filing of patents

* Plan outlay for health care enhanced to Rs.57.8 billion from Rs.49.2 billion; Rs 1.8 billion set aside for HIV / AIDS control